Sugi Predict

Sugi Predict / Compounds / SCHEMBL2552386

SCHEMBL2552386

SCHEMBL2552386

O=[C]c1ccc(Cl)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.35
▸ RAPGEF4 Q8WZA2 1/20 0.34
▸ KMO O15229 2/20 0.33
▸ KCNQ3 O43525 2/20 0.33
▸ KCNQ2 O43526 2/20 0.33
▸ KCNE1 P15382 2/20 0.33
▸ KCNQ1 P51787 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ KCNQ5 Q9NR82 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ SLC6A3 Q01959 3/20 0.33
▸ VCAM1 P19320 1/20 0.32
▸ FFAR1 O14842 2/20 0.32
▸ FFAR4 Q5NUL3 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ PPARA Q07869 1/20 0.32
▸ MAPT P10636 1/20 0.31
▸ GRM5 P41594 1/20 0.31
▸ PTGS2 P35354 2/20 0.30
▸ RAD51 Q06609 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2554329 0.82 SLC2A1 (0.43) SLC2A1MAPTPTGS2PTGS1
SCHEMBL97003 0.78 GRM5 (0.46) TDP1FFAR1FFAR4GRM5
SCHEMBL95410 0.78 MAPK1 (0.46) MAPK1TDP1SLC6A2
SCHEMBL234592 0.77 VCAM1 (0.48) VCAM1SLC6A4
SCHEMBL16955681 0.77 RAPGEF4 (0.34) RAPGEF4KMOKCNQ3KCNQ2KCNE1
SCHEMBL15094429 0.77 EGFR (0.39) RAPGEF4KMOKCNQ3KCNQ2KCNE1
SCHEMBL30480935 0.77 VCAM1 (0.48) VCAM1SLC6A4
SCHEMBL19808998 0.74 FFAR1 (0.36) SLC2A1RAPGEF4KMOKCNQ3KCNQ2
SCHEMBL8771367 0.74 CYP1A1 (0.39) RAPGEF4SLC6A3FFAR1FFAR4GRM5
SCHEMBL10834347 0.73 GRIN2D (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48335-E1 Polymyxin derivatives as antimicrobial compounds MONASH UNIVERSITY (AU) 2020-12-01 — — US claimed
CN-106414480-B Polymyxin derivatives as antimicrobial compounds 莫纳什大学 2020-08-04 — — CN claimed
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2017-05-18 — — US claimed
CN-106414480-A POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS 莫纳什大学 2017-02-15 — — CN claimed
EP-3126376-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS Monash University (AU) 2017-02-08 — — EP claimed
WO-2015149131-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2015-10-08 — — WO claimed
WO-2021225365-A1 ANTAGONISTIC SMALL MOLECULE COMPOUND HAVING TOLL-LIKE RECEPTOR 7/9 INHIBITORY FUNCTION 아주대학교산학협력단 (KR) 2021-11-11 — — WO disclosed
US-RE48335-E1 Polymyxin derivatives as antimicrobial compounds MONASH UNIVERSITY (AU) 2020-12-01 — — US disclosed
CN-106414480-B Polymyxin derivatives as antimicrobial compounds 莫纳什大学 2020-08-04 — — CN disclosed
US-20200125564-A1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS OGEDA SA (BE) 2020-04-23 — — US disclosed
US-10065960-B2 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders OGEDA SA (BE) 2018-09-04 — — US disclosed
US-9926325-B2 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders OGEDA SA (BE) 2018-03-27 — — US disclosed
EP-2257297-B1 COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION MIMETICA PTY LTD (AU) 2017-10-18 — — EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 — — CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 — — CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 — — CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 — — CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10065960-B2 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders BDKRB2, ACKR3, KLRK1 SLC2A1 3600/4885RAPGEF4 3335/4885KMO 151/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SLC2A1 2699/4885RAPGEF4 4025/4885KMO 4404/4885
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS VIP, PEPD, NRDC SLC2A1 3383/4885RAPGEF4 4101/4885KMO 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.